This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Jan;9(1):5-8.

doi: 10.2217/imt-2016-0117.

Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment

Laura C Cappelli¹, Jarushka Naidoo², Clifton O Bingham 3rd¹, Ami A Shah¹

Affiliations

Affiliations

¹ Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Baltimore MD, 21224, USA.
² Department of Oncology, Johns Hopkins School of Medicine,440 Eastern Avenue, Baltimore MD, 21224, USA.

PMID: 28000525
DOI: 10.2217/imt-2016-0117

Editorial

Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment

Laura C Cappelli et al. Immunotherapy. 2017 Jan.

. 2017 Jan;9(1):5-8.

doi: 10.2217/imt-2016-0117.

Authors

Laura C Cappelli¹, Jarushka Naidoo², Clifton O Bingham 3rd¹, Ami A Shah¹

Affiliations

¹ Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Baltimore MD, 21224, USA.
² Department of Oncology, Johns Hopkins School of Medicine,440 Eastern Avenue, Baltimore MD, 21224, USA.

PMID: 28000525
DOI: 10.2217/imt-2016-0117

No abstract available

Keywords: cancer; immune checkpoint inhibitors; immunotherapy; inflammatory arthritis.

PubMed Disclaimer

Similar articles

Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R. Prieux-Klotz C, et al. Target Oncol. 2017 Jun;12(3):301-308. doi: 10.1007/s11523-017-0495-4. Target Oncol. 2017. PMID: 28540478
Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F, Loscalzo J. Cheng F, et al. Trends Immunol. 2017 Feb;38(2):77-78. doi: 10.1016/j.it.2016.11.007. Epub 2016 Dec 2. Trends Immunol. 2017. PMID: 27919707
Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
Abdel-Rahman O, Eltobgy M, Oweira H, Giryes A, Tekbas A, Decker M. Abdel-Rahman O, et al. Immunotherapy. 2017 Nov;9(14):1175-1183. doi: 10.2217/imt-2017-0108. Immunotherapy. 2017. PMID: 29067884 Review.
The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade.
Bersanelli M, Leonetti A, Buti S. Bersanelli M, et al. Immunotherapy. 2017 Nov;9(14):1127-1131. doi: 10.2217/imt-2017-0127. Immunotherapy. 2017. PMID: 29067883 No abstract available.
Adapting Cancer Immunotherapy Models for the Real World.
Klevorn LE, Teague RM. Klevorn LE, et al. Trends Immunol. 2016 Jun;37(6):354-363. doi: 10.1016/j.it.2016.03.010. Epub 2016 Apr 19. Trends Immunol. 2016. PMID: 27105824 Free PMC article. Review.

See all similar articles

Cited by

Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Abdel-Wahab N, Suarez-Almazor ME. Abdel-Wahab N, et al. Expert Rev Clin Immunol. 2024 Aug;20(8):873-893. doi: 10.1080/1744666X.2024.2323966. Epub 2024 Mar 19. Expert Rev Clin Immunol. 2024. PMID: 38400840 Review.
Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA. Cunningham-Bussel A, et al. Arthritis Rheumatol. 2022 Mar;74(3):527-540. doi: 10.1002/art.41949. Epub 2022 Jan 25. Arthritis Rheumatol. 2022. PMID: 34397169 Free PMC article.
Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.
Hosseinikhah SM, Barani M, Rahdar A, Madry H, Arshad R, Mohammadzadeh V, Cucchiarini M. Hosseinikhah SM, et al. Int J Mol Sci. 2021 Mar 18;22(6):3092. doi: 10.3390/ijms22063092. Int J Mol Sci. 2021. PMID: 33803502 Free PMC article. Review.
PD-1/PD-L1 Inhibitors for Non-Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management.
Davies MJ. Davies MJ. J Adv Pract Oncol. 2019 Mar;10(Suppl 1):21-35. doi: 10.6004/jadpro.2019.10.2.11. Epub 2019 Mar 1. J Adv Pract Oncol. 2019. PMID: 33014515 Free PMC article. Review.
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Choi J, Lee SY. Choi J, et al. Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb. Immune Netw. 2020. PMID: 32158597 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Taylor & Francis
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information